ES2133807T3 - Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas. - Google Patents

Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.

Info

Publication number
ES2133807T3
ES2133807T3 ES95933489T ES95933489T ES2133807T3 ES 2133807 T3 ES2133807 T3 ES 2133807T3 ES 95933489 T ES95933489 T ES 95933489T ES 95933489 T ES95933489 T ES 95933489T ES 2133807 T3 ES2133807 T3 ES 2133807T3
Authority
ES
Spain
Prior art keywords
therapeutic use
peptidyl compounds
inhibitors
metaloprotease
metaloprotease inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95933489T
Other languages
English (en)
Inventor
John Montana
Andrew Douglas Baxter
David Alan Owen
Robert John Watson
Neil Phillipson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9420057A external-priority patent/GB9420057D0/en
Priority claimed from GBGB9504907.8A external-priority patent/GB9504907D0/en
Priority claimed from GBGB9509431.4A external-priority patent/GB9509431D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of ES2133807T3 publication Critical patent/ES2133807T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052Val-amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043Leu-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPUESTOS DE FORMULA GENERAL (I) TIENEN UTILIDAD COMO INHIBIDORES DE METALOPROTEINASAS DE MATRIZ Y TFN.
ES95933489T 1994-10-05 1995-10-05 Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas. Expired - Lifetime ES2133807T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9420057A GB9420057D0 (en) 1994-10-05 1994-10-05 Compounds
GBGB9504907.8A GB9504907D0 (en) 1995-03-10 1995-03-10 Compounds
GBGB9509431.4A GB9509431D0 (en) 1995-05-10 1995-05-10 Compounds

Publications (1)

Publication Number Publication Date
ES2133807T3 true ES2133807T3 (es) 1999-09-16

Family

ID=27267412

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95933489T Expired - Lifetime ES2133807T3 (es) 1994-10-05 1995-10-05 Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.

Country Status (19)

Country Link
US (2) US5994312A (es)
EP (1) EP0784629B1 (es)
JP (1) JP3787605B2 (es)
CN (1) CN1193978A (es)
AT (1) ATE179431T1 (es)
AU (1) AU695796B2 (es)
BR (1) BR9509237A (es)
CA (1) CA2201639A1 (es)
CZ (1) CZ288436B6 (es)
DE (1) DE69509401T2 (es)
DK (1) DK0784629T3 (es)
ES (1) ES2133807T3 (es)
FI (1) FI971412A7 (es)
GR (1) GR3030751T3 (es)
HU (1) HUT77282A (es)
MX (1) MX9702487A (es)
NO (1) NO971537L (es)
PL (1) PL183510B1 (es)
WO (1) WO1996011209A1 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0824544B1 (en) * 1995-05-10 2003-04-16 Darwin Discovery Limited Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use
EP0828732A1 (en) * 1995-05-10 1998-03-18 Chiroscience Limited Peptidyl compounds and their therapeutic use
DE69624477T2 (de) * 1995-05-10 2003-06-26 Darwin Discovery Ltd., Cambridge Peptide, die metallproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung
CA2217850A1 (en) * 1995-05-10 1996-11-14 Chirotech Technology Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
DK0859784T3 (da) * 1995-10-05 2003-04-22 Darwin Discovery Ltd Thiosubstituerede peptider som inhibitorer af metalloproteinaser og TNF-frigivelse
GB9523066D0 (en) * 1995-11-10 1996-01-10 Chiroscience Ltd Compounds and their therapeutic use
ES2172690T3 (es) * 1995-11-22 2002-10-01 Darwin Discovery Ltd Compuestos de mercaptoalquilpeptidil con un sustituyente de imidazol y su utilizacion como inhibidores de metaloproteinasas de matriz (mmp) y/o del factor de necrosis tumoral (tnf).
CN100413859C (zh) 1996-01-23 2008-08-27 盐野义制药株式会社 磺化的氨基酸衍生物及含有它的金属蛋白酶抑制剂
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US6811995B1 (en) * 1996-04-26 2004-11-02 Children's Medical Center Corporation Non-invasive enzyme screen for cancer
PL331338A1 (en) * 1996-07-22 1999-07-05 Monsanto Co Thiosulphonamidic metaloprotease inhibitors
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
RU2221781C2 (ru) * 1996-07-22 2004-01-20 Монсанто Компани Тиолсульфоновые соединения в качестве ингибитора матриксной металлопротеазы и способы лечения
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US6429212B1 (en) * 1996-08-16 2002-08-06 Ishihara Sangyo Kaisha Ltd. Medicinal composition
PT933379E (pt) * 1996-08-28 2006-07-31 Shionogi & Co Novos derivados peptidicos contendo um radical tiazolil-alanina
DK0928291T3 (da) * 1996-09-19 2003-03-17 Aventis Pharma Inc 3-Mercaptoacetylamino-1,5-substituerede 2-oxo-azepanderivater, der er nyttige som inhibitorer af matrixmetalloproteinase
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
GB9624817D0 (en) * 1996-11-28 1997-01-15 British Biotech Pharm Metalloproteinase inhibitors
JP2001507342A (ja) * 1996-12-17 2001-06-05 ワーナー−ランバート・コンパニー 神経疾患の治療および創傷治癒を促進するためのマトリックスメタロプロテイナーゼ阻害剤の使用
SI0946166T1 (en) * 1996-12-17 2004-06-30 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for promoting wound healing
DE69821228T2 (de) * 1997-03-03 2004-10-21 Darwin Discovery Ltd Selektive mmp inhibitoren mit verringerten nebenwirkungen
KR20000075954A (ko) 1997-03-04 2000-12-26 죤 에이치. 뷰센 N-히드록시 4-술포닐 부탄아미드 화합물
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6034136A (en) 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
WO1999007679A1 (en) * 1997-08-08 1999-02-18 Chiroscience Limited Peptidyl compounds having mmp and tnf inhibitory activity
US6319902B1 (en) 1997-08-22 2001-11-20 Shionogi & Co., Ltd. Peptide derivatives having thiazolyl-alanine residue
CA2306460A1 (en) 1997-11-14 1999-05-27 G.D. Searle & Co. Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
FI980604A0 (fi) * 1998-03-18 1998-03-18 Univ Helsinki Licensing Nya matrismetalloproteinasinhibitorer och -regulatorer
JP2002528461A (ja) * 1998-10-23 2002-09-03 ダーウィン・ディスカバリー・リミテッド 公知ペプチドメタロプロテイナーゼインヒビターの単一形態型
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
WO2000040578A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
US6486193B2 (en) * 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
KR20010102000A (ko) 1999-02-08 2001-11-15 윌리암스 로저 에이 술파마토 히드록삼산 메탈로프로테아제 억제제
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
NL1013404C2 (nl) * 1999-10-27 2001-05-01 Dsm Nv Werkwijze voor de bereiding van een dipeptide en tussenproduct in een dergelijke werkwijze.
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
AU778368B2 (en) 2000-05-15 2004-12-02 Darwin Discovery Limited Hydroxamic acid derivatives
AU2001286763C1 (en) * 2000-08-25 2006-03-02 Research Corporation Technologies, Inc. New uses for amino acid anticonvulsants for treatment of pain
TWI285110B (en) 2000-08-31 2007-08-11 Shionogi & Co Parkinson disease therapeutic agent
PT1243262E (pt) 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
DE60100055T2 (de) 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
FR2823212B1 (fr) * 2001-04-10 2005-12-02 Inst Nat Sante Rech Med Inhibiteurs de la toxine botulique de type b
YU85403A (sh) 2001-05-11 2006-03-03 Pharmacia Corporation Aromatični sulfonski hidroksamati i njihova upotreba kao proteaznih inhibitora
ES2706902T3 (es) 2001-06-26 2019-04-01 Amgen Inc Anticuerpos para OPGL
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
MXPA04010555A (es) 2002-04-25 2005-02-17 Pharmacia Corp Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
JP2006502980A (ja) * 2002-06-25 2006-01-26 ファルマシア・コーポレーション アリールスルホニルヒドロキサム酸およびアミド誘導体、ならびにプロテアーゼ阻害薬としてのそれらの使用
AU2003300379A1 (en) * 2002-12-27 2004-07-29 Angiotech Pharmaceuticals, Inc. Compositions and methods of using collagen and MMPI
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040259744A1 (en) * 2003-12-19 2004-12-23 Meidong Yang Skin and hair cleansers containing sulfur
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EA014055B1 (ru) 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
WO2008029168A2 (en) * 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
WO2009048541A2 (en) * 2007-10-05 2009-04-16 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer
EP2990051B1 (en) 2009-04-10 2016-10-26 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (mmp-1)
WO2013016531A2 (en) * 2011-07-26 2013-01-31 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer
WO2013039851A1 (en) 2011-09-12 2013-03-21 Mallinckrodt Llc Optical agents for imaging and visualization of matrix metalloproteinase enzymes
CN110143892B (zh) * 2019-06-21 2022-08-12 江苏豪森药业集团有限公司 莫沙必利中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113715A (en) * 1977-01-17 1978-09-12 E. R. Squibb & Sons, Inc. Amino acid derivatives
US4235885A (en) * 1979-06-25 1980-11-25 E. R. Squibb & Sons, Inc. Inhibitors of mammalian collagenase
US4263293A (en) * 1980-05-30 1981-04-21 E. R. Squibb & Sons, Inc. Heterocyclic containing amides as inhibitors of mammalian collagenase
US4382081A (en) * 1981-06-12 1983-05-03 E. R. Squibb & Sons, Inc. Inhibitors of mammalian collagenase
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
EP0358660B1 (en) * 1987-03-17 1994-05-25 Research Corporation Technologies, Inc. Synthetic inhibitors of mammalian collagenase
WO1992022523A2 (en) * 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
FR2679564A1 (fr) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
EP0715619A4 (en) * 1993-08-23 1997-03-19 Immunex Corp Inhibitors of tnf-alpha secretion
US5455262A (en) * 1993-10-06 1995-10-03 Florida State University Mercaptosulfide metalloproteinase inhibitors
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds

Also Published As

Publication number Publication date
HUT77282A (hu) 1998-03-30
US5994312A (en) 1999-11-30
DK0784629T3 (da) 1999-10-25
US6180611B1 (en) 2001-01-30
FI971412A0 (fi) 1997-04-04
CA2201639A1 (en) 1996-04-18
FI971412L (fi) 1997-04-04
MX9702487A (es) 1998-04-30
DE69509401T2 (de) 1999-08-19
PL183510B1 (pl) 2002-06-28
DE69509401D1 (de) 1999-06-02
GR3030751T3 (en) 1999-11-30
NO971537D0 (no) 1997-04-04
CN1193978A (zh) 1998-09-23
AU695796B2 (en) 1998-08-20
JPH10507170A (ja) 1998-07-14
JP3787605B2 (ja) 2006-06-21
NO971537L (no) 1997-06-04
AU3612795A (en) 1996-05-02
FI971412A7 (fi) 1997-04-04
PL319503A1 (en) 1997-08-18
CZ99697A3 (en) 1997-09-17
BR9509237A (pt) 1997-10-21
EP0784629B1 (en) 1999-04-28
EP0784629A1 (en) 1997-07-23
ATE179431T1 (de) 1999-05-15
WO1996011209A1 (en) 1996-04-18
CZ288436B6 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
ES2133807T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
MX9700557A (es) Dihidrobenzofuranos.
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
PT991619E (pt) Inibidores da adesao celular mediada pela alfa4beta1
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
FI961976A7 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
ES2191102T3 (es) Heterociclos de peptidilo utiles en el tratamiento de las afecciones relacionadas con la trombina.
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
ITMI942025A0 (it) Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
ES2194106T3 (es) .ompuestos de imidazol
IT1285770B1 (it) Composti corticoidei
ATE126215T1 (de) Anti-entzündende 4-aminophenol-derivate.
MX9302931A (es) Nuevas 4-aza-5&-colestan-onas 7b-substituidas como inhibidores de 5&-reductasa.
ATE433963T1 (de) Fab-i inhibitoren
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
FI964936L (fi) Bentsopyraaneja ja niiden käyttö terapeuttisina aineina
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
DK1294732T3 (da) Ruthenium (II)-forbindelser til anvendelse i cancerterapi
BG100248A (bg) Инхибитори на скваленсинтетаза
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 784629

Country of ref document: ES